COMMENTARY

• Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
  January 23, 2012

• Will New Drug Makers Dominate Domestic Biosimilars Market?
  December 26, 2011

• Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
  December 12, 2011

• “Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
  November 28, 2011

• Perpetuation of Premium for New Drug Development Faces Hurdles
  November 14, 2011

• Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
  November 14, 2011

• Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
  October 19, 2011

• Pinning Hope on Academia in Seeking a Radical Cure for AD
  October 10, 2011

• New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
  October 3, 2011

• Discussions on Amendment of PAL Now in Final Stages
  October 3, 2011

• Korosho Revises GL for Drafting, Distributing Drug Safety Information
  September 5, 2011

• Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
  August 29, 2011

• Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
  August 8, 2011

• Current Promising Drug Candidates with a New Mode of Action
  August 8, 2011

• Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
  July 18, 2011

• Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
  July 4, 2011

• Era of Competition Dawns in Market for AD Treatments
  June 27, 2011

• Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
  June 20, 2011

• Return to Full-bore Growth Strategy Risky for Taiyo Pharm
  June 13, 2011

• Why the Same Mistake Repeated? -MSD's Promotion Code Violations
  June 6, 2011

ページ